BioAtla Inc (BCAB) concluded trading on Wednesday at a closing price of $3.37, with 4.08 million shares of worth about $13.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 129.25% during that period and on May 01, 2024 the price saw a gain of about 49.45%. Currently the company’s common shares owned by public are about 48.08M shares, out of which, 38.77M shares are available for trading.
Stock saw a price change of 43.40% in past 5 days and over the past one month there was a price change of -4.26%. Year-to-date (YTD), BCAB shares are showing a performance of 36.99% which decreased to -5.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.24 but also hit the highest price of $4.07 during that period. The average intraday trading volume for BioAtla Inc shares is 554.69K. The stock is currently trading 17.23% above its 20-day simple moving average (SMA20), while that difference is up 21.53% for SMA50 and it goes to 46.52% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioAtla Inc (NASDAQ: BCAB) currently have 48.08M outstanding shares and institutions hold larger chunk of about 54.38% of that.
The stock has a current market capitalization of $162.13M and its 3Y-monthly beta is at 1.21. It has posted earnings per share of -$2.58 in the same period. It has Quick Ratio of 4.11 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCAB, volatility over the week remained 19.73% while standing at 11.82% over the month.
Stock’s fiscal year EPS is expected to rise by 25.09% while it is estimated to increase by 8.17% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on September 15, 2022 offering a Mkt outperform rating for the stock and assigned a target price of $17 to it. Coverage by Credit Suisse stated BioAtla Inc (BCAB) stock as a Neutral in their note to investors on May 05, 2022, suggesting a price target of $5 for the stock. On March 21, 2022, H.C. Wainwright Initiated their recommendations, while on October 15, 2021, BTIG Research Resumed their ratings for the stock with a price target of $68. Stock get a Buy rating from ROTH Capital on June 28, 2021.
